Doctors Healthcare Innovation Population Health Rehabilitation 
Health Blawg
DECEMBER 10, 2018
criminal enforcement vs. treatment and rehabilitation) we have a natural experiment that can yield data to be looked at in a cost-effectiveness analysis. As Peter observed, it is challenging to include the non-health costs and benefits in the analysis. Given the differences in state-by-state approaches to the opioid epidemic (e.g
Health Blawg
DECEMBER 10, 2018
criminal enforcement vs. treatment and rehabilitation) we have a natural experiment that can yield data to be looked at in a cost-effectiveness analysis. As Peter observed, it is challenging to include the non-health costs and benefits in the analysis. Given the differences in state-by-state approaches to the opioid epidemic (e.g
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Health Blawg
DECEMBER 10, 2018
criminal enforcement vs. treatment and rehabilitation) we have a natural experiment that can yield data to be looked at in a cost-effectiveness analysis. As Peter observed, it is challenging to include the non-health costs and benefits in the analysis. My guest for this edition of Harlow on Healthcare is Peter Neumann.
Health Blawg
DECEMBER 10, 2018
criminal enforcement vs. treatment and rehabilitation) we have a natural experiment that can yield data to be looked at in a cost-effectiveness analysis. As Peter observed, it is challenging to include the non-health costs and benefits in the analysis. My guest for this edition of Harlow on Healthcare is Peter Neumann.
Health Blawg
DECEMBER 10, 2018
criminal enforcement vs. treatment and rehabilitation) we have a natural experiment that can yield data to be looked at in a cost-effectiveness analysis. As Peter observed, it is challenging to include the non-health costs and benefits in the analysis. My guest for this edition of Harlow on Healthcare is Peter Neumann.
Health Blawg
DECEMBER 10, 2018
criminal enforcement vs. treatment and rehabilitation) we have a natural experiment that can yield data to be looked at in a cost-effectiveness analysis. As Peter observed, it is challenging to include the non-health costs and benefits in the analysis. My guest for this edition of Harlow on Healthcare is Peter Neumann.
Expert insights. Personalized for you.
60 
Let's personalize your content